Breast Adenocarcinoma — Trials

Breast Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,713 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 686
Recruiting: 381
Ph III recruiting: 45
Growth YoY: +8.5%
Industry share: 24%
Top sponsor: Fudan University
Termination share: 44.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (278)

clinicaltrialsPublishedShowing 1–45 of 45 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06058377	Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	recruiting	Phase 3	3,680	National Cancer Institute (NCI)NIH	2	Sep 29, 2026	clinicaltrials
NCT06627712	SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC	recruiting	Phase 3	318	West China HospitalOTHER	1	Sep 29, 2026	clinicaltrials